[Federal Register Volume 71, Number 133 (Wednesday, July 12, 2006)]
[Rules and Regulations]
[Pages 39204-39205]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-10878]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558


New Animal Drugs for Use in Animal Feeds; Melengestrol, 
Lasalocid, and Tylosin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

[[Page 39205]]

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of an abbreviated new animal drug 
application (ANADA) filed by Ivy Laboratories, Div. of Ivy Animal 
Health, Inc. The ANADA provides for use of single-ingredient Type A 
medicated articles containing melengestrol, lasalocid, and tylosin to 
make three-way combination drug Type C medicated feeds for heifers fed 
in confinement for slaughter.

DATES: This rule is effective July 12, 2006.

FOR FURTHER INFORMATION CONTACT: Daniel A. Benz, Center for Veterinary 
Medicine (HFV-104), Food and Drug Administration, 7500 Standish Pl., 
Rockville, MD 20855, 301-827-0223, e-mail: [email protected].

SUPPLEMENTARY INFORMATION: Ivy Laboratories, Div. of Ivy Animal Health, 
Inc., 8857 Bond St., Overland Park, KS 66214, filed ANADA 200-430 for 
use of HEIFERMAX 500 (melengestrol acetate) Liquid Premix, BOVATEC 
(lasalocid), and TYLAN (tylosin phosphate) single-ingredient Type A 
medicated articles to make dry and liquid, three-way combination drug 
Type C medicated feeds for heifers fed in confinement for slaughter. 
Ivy Laboratories' ANADA 200-430 is approved as a generic copy of NADA 
138-992, sponsored by Pharmacia and Upjohn Co., a Division of Pfizer, 
Inc., for combination use of MGA 500 (melengestrol acetate) Liquid 
Premix, BOVATEC, and TYLAN in cattle feed. The application is approved 
as of June 1, 2006, and the regulations are amended in 21 CFR 558.342 
to reflect the approval. The basis of approval is discussed in freedom 
of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    The agency has determined under 21 CFR 25.33(a)(2) that this action 
is of a type that does not individually or cumulatively have a 
significant effect on the human environment. Therefore, neither an 
environmental assessment nor an environmental impact statement is 
required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subject in 21 CFR Part 558

    Animal drugs, Animal feeds.

0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is 
amended as follows:

PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

0
1. The authority citation for 21 CFR part 558 continues to read as 
follows:

    Authority: 21 U.S.C. 360b, 371.


Sec.  558.342  [Amended]

0
2. In Sec.  558.342, amend the table in paragraph (e)(1)(iv) in the 
``Sponsor'' column by adding in numerical sequence ``021641''.

    Dated: June 23, 2006.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. E6-10878 Filed 7-11-06; 8:45 am]
BILLING CODE 4160-01-S